Log in

NASDAQ:AGIOAgios Pharmaceuticals Price Target & Analyst Ratings

+1.63 (+3.60 %)
(As of 08/3/2020 04:00 PM ET)
Today's Range
Now: $46.95
50-Day Range
MA: $51.36
52-Week Range
Now: $46.95
Volume733,861 shs
Average Volume694,006 shs
Market Capitalization$3.23 billion
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Agios Pharmaceuticals in the last 12 months. Their average twelve-month price target is $69.83, suggesting that the stock has a possible upside of 48.74%. The high price target for AGIO is $82.00 and the low price target for AGIO is $49.00. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.772.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $69.83$69.67$65.18$65.50
Price Target Upside: 48.74% upside45.44% upside76.12% upside34.41% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/31/2020Cantor FitzgeraldBoost Price TargetOverweight$70.00 ➝ $72.00High
7/31/2020Canaccord GenuityReiterated RatingBuy$72.00High
7/30/2020Needham & Company LLCInitiated CoverageBuy$71.00High
6/15/2020SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $72.00Medium
6/15/2020GuggenheimBoost Price TargetBuy$60.00 ➝ $66.00Medium
6/15/2020CitigroupBoost Price TargetBuy$64.00 ➝ $75.00Medium
6/15/2020OppenheimerReiterated RatingHoldMedium
6/12/2020Piper SandlerBoost Price TargetOverweight$70.00 ➝ $80.00High
5/4/2020JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $82.00High
3/4/2020BarclaysInitiated CoverageEqual Weight$50.00High
3/4/2020CowenReiterated RatingBuyHigh
12/9/2019BMO Capital MarketsBoost Price TargetOutperform$45.00 ➝ $49.00High
11/1/2019Royal Bank of CanadaSet Price TargetBuy$79.00N/A
10/28/2019Piper Jaffray CompaniesLower Price TargetOverweight$80.00 ➝ $70.00High
5/23/2019Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$55.00Medium
7/23/2018SunTrust BanksReiterated RatingBuy$123.00Low
5/7/2018Credit Suisse GroupSet Price TargetBuy$95.00Low
2/14/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
(Data available from 8/4/2018 forward)
This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.